Mirae Asset Global Investments Co. Ltd. Grows Stake in Genmab A/S (NASDAQ:GMAB)

Mirae Asset Global Investments Co. Ltd. boosted its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 229.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,727 shares of the company's stock after purchasing an additional 34,652 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Genmab A/S were worth $1,033,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GMAB. Two Sigma Advisers LP increased its position in Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after acquiring an additional 280,900 shares during the period. Natixis Advisors LLC increased its position in Genmab A/S by 29.8% in the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock valued at $5,036,000 after acquiring an additional 47,437 shares during the period. FMR LLC increased its position in Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company's stock valued at $6,782,000 after acquiring an additional 33,076 shares during the period. Verition Fund Management LLC acquired a new position in Genmab A/S in the 3rd quarter valued at approximately $709,000. Finally, Mediolanum International Funds Ltd acquired a new position in Genmab A/S in the 3rd quarter valued at approximately $699,000. Institutional investors own 7.07% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GMAB. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target for the company in a research report on Thursday. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday. Finally, BMO Capital Markets reiterated an "outperform" rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Genmab A/S currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.17.

Genmab A/S Stock Up 1.8 %

GMAB traded up $0.38 during midday trading on Friday, hitting $21.30. The company had a trading volume of 2,417,574 shares, compared to its average volume of 1,682,134. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.88. The company has a market capitalization of $14.10 billion, a price-to-earnings ratio of 20.68, a PEG ratio of 0.54 and a beta of 0.96. The stock's 50 day moving average price is $20.65 and its 200 day moving average price is $23.15.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. Research analysts predict that Genmab A/S will post 1.25 EPS for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.